dividual session that examined the ability to detect and treat thyroid dysfunction during pregnancy. For this session, presented papers included: "Laboratory Reference Values in Pregnancy" and "Criteria for Diagnosis and Treatment of Hypothyroidism in Pregnancy." These presentations were formally discussed by invited respondents and by others in attendance. Salient points from this session about which there was agreement include the following: thyrotropin (TSH) can be used as marker for hypothyroidism in pregnancy, except when there is iodine deficiency usually evidenced by elevated serum thyroglobulin (Tg). We need more longitudinal studies of TSH during pregnancy in iodine-sufficient populations without evidence of autoimmune thyroid disease to develop trimester-specific TSH reference ranges. Current free thyroxine (FT 4 ) estimate methods are sensitive to abnormal binding-protein states such as pregnancy. There is no absolute FT 4 value that will define hypothyroxinemia across methods. Total thyroxine (TT 4 ) changes in pregnancy are predictable and not method-specific. TT 4 below 100 nmol/L (7.8 g/dL) is a reasonable indicator of hypothyroxinemia in pregnancy. Women with known hypothyroidism and receiving levothyroxine (LT 4 ) before pregnancy should plan to increase their dosage by 30% to 60% early in pregnancy. Women with autoimmune thyroid disease prior to pregnancy are at increased risk for thyroid insufficiency during pregnancy and postpartum thyroiditis and should be monitored with TSH during pregnancy.
Introduction

T
HIS REPORT contains the summaries of several papers presented at a workshop held in Atlanta, Georgia, January [12] [13] 2004 , to address "The Impact of Maternal Thyroid Diseases on the Developing Fetus: Implications for Diagnosis, Treatment, and Screening." The purpose of this session was to examine the ability to detect and treat thyroid dysfunction. This session was organized and moderated by Dr. Susan Mandel.
"Laboratory Reference Values in Pregnancy" -Dr. Carole A. Spencer
The complex hormonal changes affecting free thyroxine (FT 4 ) availability to mother and fetus have been described earlier at this workshop by Dr. Daniel Glinoer (1) . In view of the coordinated trimester-specific changes in thyrotropin (TSH) and FT 4 occurring during pregnancy and the vulnerability of the fetus during the first trimester before the fetal thyroid becomes active, trimester-specific TSH and FT 4 reference ranges are needed for evaluating pregnant patients (Fig. 1 ). Nonpregnant reference ranges may be misleading during the rapidly changing hormonal environment of pregnancy. During pregnancy, TSH is a more sensitive marker of thyroid status than FT 4 , just as it is in nonpregnant patients, and it reflects the physiologic log/linear relationship of TSH to FT 4 . Reference ranges for TSH and other thyroid tests are typically established from an appropriate cohort of subjects that have been rigorously selected as being euthyroid. Iodine insufficiency and autoimmune thyroid conditions (using thyroid peroxidase antibodies [TPOAb] as a marker) are critical exclusion criteria when selecting a cohort of patients, pregnant or not, for reference range determination purposes.
• Much of the data have been generated in iodine-deficient populations and cannot be considered as normative data.
• There have been few large longitudinal studies that have included first trimester values.
• Few studies have rigorously excluded individuals with autoimmune thyroid disease, usually determined by the presence of TPOAb; inclusion of such individuals skews reference data.
• Current FT 4 methodology is problematic in that it is sensitive to the thyroxine-binding globulin (TBG) and/or albumin abnormalities characteristic of pregnancy in a method-specific and unpredictable manner.
Unfortunately, currently there are no reliable trimesterspecific reference ranges for TSH. In addition to the problems listed above, the current available studies included early studies that use methods unable to detect the low TSH levels typical of the first trimester. The inclusion of patients with unusually high human chorionic gonadotropin (hCG), such as those pregnancies with severe hyperemesis (2, 3) or with twin pregnancies (4), will skew the TSH lower reference limits. There is consensus, however, that the TSH reference range for first-trimester pregnancy should be lower than that for nonpregnant subjects (Fig. 2) (5) . Until better data are available, the new recommended nonpregnant upper limit for TSH of 2.5 mIU/L (6) is an appropriate conservative upper TSH limit for first trimester pregnancy. Inasmuch as between-method biases for TSH are minimal, as future studies progress in pregnancy, there is no need for method-specific TSH ranges.
Our big challenge is to establish trimester-specific reference ranges for FT 4 . Although we have generally considered equilibrium dialysis the most reliable method, equilibrium dialysis is too technically complex and expensive for routine use so that clinical laboratories typically use a commercial free thyroxine estimate test (FT 4 E) test and not direct equilibrium dialysis. These FT 4 E tests are all binding-protein sensitive to some extent in a method-specific manner (7). Currently, most FT 4 testing in clinical laboratories is based on two-step or labeled antibody methodology and do not measure free hormone directly. There are no appropriate trimester-specific, method-specific reference ranges for current FT 4 E methods. Clearly no universal absolute FT 4 value can be established to define a low FT 4 across methods ( Fig.  3) (8) .
Perhaps we ought to reevaluate the clinical utility of our oldest thyroid test, total thyroxine (TT 4 ), in the setting of pregnancy. In contrast to FT 4 , TT 4 methodology is more reliable. The TT 4 reference range for nonpregnant subjects has remained stable for more than two decades and is not method-dependent (9) (10) (11) (12) (13) (14) (15) . These studies in populations with different iodine intakes and using different methodologies reveal remarkably comparable TT 4 values, both on an absolute and relative basis.
The TT 4 increase in pregnancy is predictable (1.5 times nonpregnant levels) and primarily relates to increased TBG. It is therefore appropriate at this time to use TT 4 in preference to FT 4 to evaluate pregnant patients provided that the nonpregnant reference limits are adjusted by a factor of 1.5 (16) . A TT 4 cutoff of 100 nmol/L (7.8 g/dL) may be appropriate for detecting a low FT 4 state in pregnancy (17) . Unfortunately, TT 4 testing is increasingly becoming unavailable as laboratories replace TT 4 methods with FT 4 E tests that are less reliable in the setting of pregnancy.
In considering establishing reference ranges for pregnancy, several problems need to be recognized: (1) current However, it is cheaper for the companies to go abroad, which is what they are doing.
Dr. Stephen LaFranchi: What is the ideal screening test to use as early as possible in pregnancy (4-6 weeks)?
TSH, since its suppression in the first trimester is reciprocal with the hCG, and in those with some degree of thyroid impairment, especially autoimmunity. TSH and TT 4 are probably the best combination of tests to evaluate the pregnant patient. The TSH upper range would probably be closer to 2.0, but 2.5 is a conservative limit for a first trimester pregnancy.
Dr. James E. Haddow: Our first-trimester TSH data used a cutoff of 4 mIU/L, which we felt gave our study firm ground to know who will have a problem or not. A lower cutoff will dilute the population. If 2.0 is used, what percent of population do you lose?
The Hong Kong study's TSH upper limit was 2.3 mIU/L for the first trimester, but did not exclude AITD. If 2.5 is considered the upper limit this would indicate those with TPOAb and abnormal TSH, and predict postpartum thyroiditis. Primary hypothyroidism during pregnancy can be detected by serum TSH measurement, but trimester-specific TSH normal ranges are needed because there are normal physiologic changes in serum TSH levels during gestation that may confound interpretation. In the absence of guidelines for universal screening for hypothyroidism, there are four groups of women at risk for thyroid deficiency during pregnancy.
1. Established hypothyroidism prior to pregnancy. Prior to conception, a woman may already be receiving T 4 therapy for diagnosed hypothyroidism. Using the data from NHANES III, T 4 therapy should be optimized prior to conception by titrating the dose to a serum TSH level less than 2.5mIU/L. There are now nine studies that have shown that the majority of hypothyroid women require an increase in thyroxine dose during pregnancy (Table 1 ) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The majority of women will require a dosage increase in the first trimester as determined by a serum TSH level above the normal range for that assay rather than by pregnancy-specific TSH ranges. The median time of dosage increase is 8 weeks' gestation (19) . The required T 4 dosage increment to normalize the serum TSH level may depend upon both the degree of the initial serum TSH elevation ( Fig. 4 ) (22) and the etiology of the maternal hypothyroidism (22) . Of studies that delineated the hypothyroid women, 35%-45% with AITD required a dosage increase, as opposed to 70%-75% of athyreotic women (e.g., from 131 I ablation or thyroidectomy) ( Fig. 5 ) (22) . If trimester-specific TSH normal ranges were used, the dosage of even more hypothyroid women would probably increase. The median thyroxin increment of the nine studies was approximately 39 g/d with athyreotic women requiring a larger increase (mean, 52 g/d) than those with lymphocytic thyroiditis (mean, 28 g/d) (19) . The thyroxine dosage should be titrated to gestation spe- During pregnancy, the prevalence of serum TSH levels above normal assay reference ranges (not pregnancy reference ranges) is 1%-2% (22, 31) . In the vast majority of such women, subsequent measurement of thyroid hormone levels falls in the normal assay range, with only a small fraction having overt hypothyroidism. The optimal therapy for these women is titration of T 4 therapy to trimester-specific normal TSH ranges. On average, the increased T 4 requirement during pregnancy is approximately 2 /kg per day for replacement dosing, rather than 1.6 g/kg per day used for the nonpregnant patient.
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Treatment recommendations were:
• Initiate LT 4 therapy if serum TSH greater than 2.5 mIU/L (confirmed) prior to pregnancy.
• Titrate LT 4 to serum TSH at less than 2.5 mIU/L prior to pregnancy for women with established hypothyroidism and women who have just begun LT 4 therapy.
• Check serum TSH level in early pregnancy.
• Base LT 4 dosage adjustments during pregnancy upon trimester-specific TSH normal ranges. That is a critically important point. I was restricting myself to hypothyroidism in the absence of iodine deficiency-so I didn't include iodine deficiency or borderline iodine deficiency as a risk factor. But I do think that's a critical point that I think was made yesterday. Perhaps one of the things that will come out of this meeting is an emphasis on ensuring iodine health worldwide for women in their reproductive years.
Dr. John H. Lazarus: Should the risk factor of an iodine deficient area be better accounted for, especially before using T 4 ?
Yes, that is a critical point. This presentation addressed hypothyroidism in the absence of iodine deficiency, but perhaps iodine should be supplemented for reproductive-age women worldwide.
Dr. Robert C. Smallridge: Is there any danger to overtreating? What is known about suppressed TSH in very mild FT 4 elevations during pregnancy and subtle changes at the other end of the TSH spectrum?
As Dr. Vulsma mentioned yesterday, there is the rare risk of central congenital hypothyroidism that resulted from Graves' disease during pregnancy, but this has not been found in someone who is exogenously treated, so that particular risk to the baby is not an issue. In terms of complication to the mother, it is plausible that miscarriage rates may rise somewhat. It is possible that mild over treatment can do harm. But "over treatment" needs definition based on normal pregnancy ranges, and the ability to diagnose over treatment may be limited by methodological issues.
Dr. Smallridge advised caution to avoid unintended effects. The Colorado study indicated that of nonpregnant individuals on thyroid hormone, 40% were on an incorrect dose, and half of those had suppressed TSHs.
It is unlikely that someone pregnant would be overtreated if appropriate TSH testing guidelines are followed. Brown presented information on the cognitive outcome in children after tsh receptor blocking antibody-induced congenital hypothyroidism: a model of fetal and maternal hypothyroidism. She pointed out that TSH receptor blocking antibodies (Abs), present in the pregnant mother, being IgGs, can be transmitted transplacentally to the fetus and, if sufficiently potent, can be a cause of both fetal and maternal hypothyroidism. Because, by analogy with rodent data, the TSH receptor is not expressed until ap-proximately 13 weeks' gestation and not upregulated until the serum TSH begins to rise in the second half of pregnancy (33, 34) , fetal hypothyroidism in this model is dependent upon maternal hypothyroidism alone in the first half of pregnancy, and combined fetal and maternal hypothyroidism in the second half. Studies in Japan have reported severe cognitive delay (mean IQ 67, range 54-76) in 5 of 23 babies with TSH receptor blocking Ab-induced congenital hypothyroidism (CH) despite early and adequate postnatal therapy. In contrast, we observed no difference in verbal, performance, or full-scale IQ in 6 babies with transient CH caused by TSH receptor blocking Abs compared to their sibling controls (full-scale IQ 108 Ϯ 21 versus 104 Ϯ 17.7). In three of these mothers, this occurred despite severe hypothyroidism in the first trimester (mean T 4 1.1 g/dL, mean TSH 44 mU/L) that required as much as 0.3 mg to 0.45 mg LT 4 to normalize. In contrast to the Japanese mothers all of whom had severe hypothyroidism in the third trimester of pregnancy, the serum T4 or FT 4 in all the mothers we studied was normal, and the TSH was either normal or mildly elevated in the third trimester.
Dr. Gabriella Morreale de Escobar
In summary:
1. TSH receptor blocking Ab-induced CH, a model of combined maternal and fetal hypothyroidism during gestation, is associated with more severe cognitive delay than either fetal or maternal hypothyroidism alone, probably because maternal T 4 is unavailable to compensate for the fetal hypothyroidism 2. This disorder should be suspected if unusually high doses of LT 4 are required to normalize maternal thyroid function during gestation, 3. In contrast to the Japanese data (34) with the author's data (35) , it appears that adequate maternal T 4 replacement in the latter half of pregnancy may be protective for fetal neurologic development even if blocking antibodies are present.
She hypothesized that:
• The most critical time for thyroid hormone-dependent brain development may be the third trimester and not earlier during pregnancy.
• Because the third trimester is important for cerebellar development as well as myelination, inadequate treatment of mothers with TSH receptor blocking Abs during pregnancy may result in more severe neurologic impairment of their babies than is seen in other causes of CH.
The conclusion was that it is critical to know the etiology of maternal hypothyroidism in order to evaluate the critical time for fetal cognitive development. If only maternal hypothyroidism is present, the first half of pregnancy is critical. But if both maternal hypothyroidism and fetal hypothyroidism are present, as with blocking antibodies or iodine deficiency, the data are consistent that the third trimester seems to be the critical period. This has important implications to the optimal timing of maternal thyroid screening.
The discussion included that a number of the women were diagnosed and treated in the first trimester, but it took time to normalize their levels, and some remained hypothyroid despite treatment.
Dr. Joanne Rovet noted that using only the full IQ score does not include other abilities related to thyroid hormone, such as attention and memory and executive processing. There may still be deficits in the children exposed in the first two trimesters that would not be measured by the presented variables. Discussant: Dr. G. Robert DeLong presented data on timing of iodine repletion of pregnant women in southern China from Studies in Xinjian Uyghur Autonomous Province, China. His studies pointed out a need for iodine during gestation for fetal development and also a role for thyroid hormone and iodine in system generation.
Studies were done in Hotien County of Xinjiang province in China (36) . This is an area of severe iodine deficiency populated by a central Asian, Turkik people. At the time of study, the conventional wisdom was that iodine was essential in the first trimester for brain formation. But the birth abnormalities of the first trimester did not parallel the conditions seen in iodine deficiency. The cohort consisted of children from age 3 years down to newborns. They were treated as soon as they were examined, as were pregnant women in all trimesters. Three measures of outcome were used: neurologic examination (a subtle, hard-to-quantify instrument), DQ and IQ (age 2 and later age 6 years), and head circumference (very quantifiable).
The time of treatment with iodine correlated well with head circumference. The incidence of microcephaly (defined as anything Ͼ 2 standard deviations from the American norm) was 20%. Treating the mothers in the third trimester showed little difference to those not treated or treated just after birth, but the infants did improve after approximately a year. Those treated in the second trimester had significantly fewer neurologic abnormalities than those not treated. However, the head circumference did not improve for those treated in the first trimester, and the outcomes of those who were treated in the early part of the first trimester paralleled those who were untreated.
Head circumference has a virtually straight-line relationship to brain weight in young children, and so serves as a good index of brain growth. Measures of head circumference versus time of iodination were charted. Those untreated at age 2 had a small head, but head circumference increased among those treated earlier. A 20-point IQ/DQ difference was also charted between those treated in the second trimester versus those untreated. More extensive testing at age 5 years showed the same pattern, although more exaggerated for improvement of those treated in the second trimester and worse for those untreated. Summary: It was concluded that the end of the second trimester appears to be a critical time for iodine, and thus for thyroid hormone, to be present to prevent permanent brain impairment. This corresponds with data from laboratory animals, and most intriguingly with experience in supplementing premature infants with thyroid hormone, which demonstrated a significant 18-point improvement in DQ at age 2 years if supplementation occurred before 27 weeks' gestational age.
An interesting and potentially related finding was drawn from a study of treating premature infants with thyroid hormone. If done after 27 weeks of pregnancy (third trimester), there was no benefit; there might even have been a slight decrease in DQ at 2 years. If treated before 27 weeks, the out-come was a positive improvement in DQ of 18 points by age 2.
Another intervention, treating the entire population with adequate iodine by adding it to drip irrigation water, succeeded in reducing infant mortality rates, particularly neonatal rates, by 50% (37) . He speculated that thyroid hormone and iodine are essential to develop the systems that are critical in preventing infant mortality through abnormalities in the immunological, cardiovascular, and other systems. There is very little information in the literature on this.
Discussion included: A participant asked: Why were early treatments in your study as bad as none at all?
The theory is that the iodized oil dissipates after an initial boost. That is correct. The study examined the children of officials of the same ethnicity, but with a better standard of living, who eat well and get plenty of iodine. They matched the American norms.
Dr. Morreale: In the later studies, where iodine was added to the water, do the data of children in the first trimester, when the iodine addition began, show a worse outcome than those in the second trimester?
There are no such data. The addition was a gradual process, inserting iodine into the crops and food over 2-3 years. Dr. Vulsma reported a pregnant Dutch woman who was euthyroid, but who received iodized oil in Africa. The child, delivered months later, was severely hypothyroid with very high iodine content, but otherwise appeared to be a normal, healthy child. He was treated with T 4 .
Dr
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session. We recognize the able assistance of Micah Milton, Martha Brocato, and Marie Murray, who organized, recorded, and transcribed this session, making this summary effort much easier.
